{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-005702","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.356425+00:00","generated_at":"2026-06-19T06:51:49.820485+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Propanc Biopharma issues $111,111 convertible note to ONE44 Capital LLC","bullets":["Principal $111,111; net proceeds $100,000 after $11,111 original issue discount.","Interest 10% per annum, payable in common stock; maturity Feb 14, 2024.","Conversion price at 60% of lowest trading price over prior 10 days (50% if DTC chill).","Prepayment allowed within 180 days with premiums of 120%-135% of face amount.","Proceeds used for general working capital; note issued under Section 4(a)(2) exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-005702","json":"https://secwatch.observer/filing/0001493152-23-005702.json","markdown":"https://secwatch.observer/filing/0001493152-23-005702.md","text":"https://secwatch.observer/filing/0001493152-23-005702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223005702/0001493152-23-005702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223005702/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:51:49.820485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b126bea6a82226c52ec907ea443e41ebd83c924","claim":"Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $111,111 with ONE44 Capital LLC at 10% per annum maturing February 14, 2024.","evidence_excerpt":"On February 14, 2023, Propanc Biopharma, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $111,111, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of ONE44.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223005702/0001493152-23-005702-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"aggregate principal amount of $111,111"},{"label":"Counterparty","value":"ONE44 Capital LLC"},{"label":"Rate","value":"10% per annum"},{"label":"Maturity","value":"February 14, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"0f0e5597dd8422adc177b953c4a6457ebfe36ac9","claim":"Propanc Biopharma, Inc. entered into Purchase Agreement with ONE44 Capital LLC valued at aggregate principal amount of $111,111 (effective 2023-02-14).","evidence_excerpt":"On February 14, 2023, Propanc Biopharma, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $111,111","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517681/000149315223005702/0001493152-23-005702-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"ONE44 Capital LLC"},{"label":"Value","value":"aggregate principal amount of $111,111"},{"label":"Effective","value":"2023-02-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}